Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1/2 Study of RCT2100 in Healthy Volunteers and Participants with Cystic Fibrosis
2024-512169-15-00Phase 2Completed
- Sponsor
- ReCode Therapeutics
- Start
- Jul 2024
- Modality
- mRNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems, Inhalation Devices → Device-based Delivery → Drug Delivery Systems
- Countries
- 5
01
Overview
Phase 2 trial of RCT2100 in cystic fibrosis (CF) (2 arms), sponsored by ReCode Therapeutics. Primary endpoint: Safety and tolerability. Started Jul 2024; status: completed.
02
Drugs
RCT2100
03
Conditions
cystic fibrosis (CF)
Beyond the preview
Go deeper on 2024-512169-15-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-512169-15-00.